Cargando…

4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design

Oncological diseases have currently reached an epidemic scale, especially in industrialized countries. Such a situation has prompted complex studies in medicinal chemistry focused on the research and development of novel effective anticancer drugs. In this review, the data concerning new 4-thiazolid...

Descripción completa

Detalles Bibliográficos
Autores principales: Roszczenko, Piotr, Holota, Serhii, Szewczyk, Olga Klaudia, Dudchak, Rostyslav, Bielawski, Krzysztof, Bielawska, Anna, Lesyk, Roman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654980/
https://www.ncbi.nlm.nih.gov/pubmed/36361924
http://dx.doi.org/10.3390/ijms232113135
Descripción
Sumario:Oncological diseases have currently reached an epidemic scale, especially in industrialized countries. Such a situation has prompted complex studies in medicinal chemistry focused on the research and development of novel effective anticancer drugs. In this review, the data concerning new 4-thiazolidinone-bearing hybrid molecules with potential anticancer activity reported during the period from the years 2017–2022 are summarized. The main emphasis is on the application of molecular hybridization methodologies and strategies in the design of small molecules as anticancer agents. Based on the analyzed data, it was observed that the main directions in this field are the hybridization of scaffolds, the hybrid-pharmacophore approach, and the analogue-based drug design of 4-thiazolidinone cores with early approved drugs, natural compounds, and privileged heterocyclic scaffolds. The mentioned design approaches are effective tools/sources for the generation of hit/lead compounds with anticancer activity and will be relevant to future studies.